Literature DB >> 18446506

Pharmacokinetics of 1,4-butanediol in rats: bioactivation to gamma-hydroxybutyric acid, interaction with ethanol, and oral bioavailability.

Ho-Leung Fung1, Pei-Suen Tsou, Jurgen B Bulitta, Doanh C Tran, Nathaniel A Page, David Soda, Sun Mi Fung.   

Abstract

1,4-Butanediol (BD), a substance of abuse, is bioactivated to gamma-hydroxybutyrate (GHB), but its fundamental pharmacokinetics (PK) have not been characterized. Because this bioactivation is partly mediated by alcohol dehydrogenase, we hypothesized that there may also be a metabolic interaction between ethanol (ETOH) and BD. We therefore studied, in rats, the plasma PK of GHB, BD and ETOH each at two intravenous (IV) doses, when each substance was given alone, and when GHB or BD was co-administered with ETOH. Results showed that bioconversion of intravenously administered BD to GHB was complete, and that both GHB and BD exhibited nonlinear PK. Various population PK models were analyzed using NONMEM VI, and the best disposition model was found to include two PK compartments each for BD, an (unmeasured) putative semialdehyde intermediate (ALD), GHB and ETOH, the presence of nonlinear (Michaelis-Menten) elimination for each compound, and several mutual inhibition processes. The most prominent mutual metabolic inhibition was found between ETOH and BD, while that between GHB and ETOH was not significant. In vitro studies using liver homogenates confirmed mutual metabolic inhibitions between GHB and BD. Oral absorption of BD was best described by a first-order process with lag-time and pre-systemic metabolism from BD to ALD. Oral absorption of BD (as BD plus ALD) was rapid and complete. The fraction of the absorbed dose entering the central compartment as BD was 30% for the 1.58 mmol/kg dose and 55% for the 6.34 mmol/kg dose. At 6.34 mmol/kg IV, the onset of loss of righting reflex (LRR) for BD was significantly delayed vs. that produced by GHB (72.0 +/- 9.1 min vs. 6.7 +/- 0.6 min, respectively, p < 0.001), and the total duration of LRR was prolonged for BD vs. GHB (192 +/- 28 min vs. 117 +/- 2 min, respectively, p < 0.05). Relative to IV dosing, oral BD produced similar but more variable LRR effects. These results may provide a quantitative PK framework for the understanding of the toxicokinetics and toxicodynamics of both BD and GHB.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18446506      PMCID: PMC2751451          DOI: 10.1208/s12248-007-9006-3

Source DB:  PubMed          Journal:  AAPS J        ISSN: 1550-7416            Impact factor:   4.009


  18 in total

1.  Protein measurement with the Folin phenol reagent.

Authors:  O H LOWRY; N J ROSEBROUGH; A L FARR; R J RANDALL
Journal:  J Biol Chem       Date:  1951-11       Impact factor: 5.157

Review 2.  NTP summary report on the metabolism, disposition, and toxicity of 1,4-butanediol (CAS No. 110-63-4).

Authors:  R D Irwin
Journal:  Toxic Rep Ser       Date:  1996-05

Review 3.  An allometric model for predicting blood ethanol elimination in mammals.

Authors:  H Matsumoto; Y Minowa; Y Nishitani; Y Fukui
Journal:  Biochem Pharmacol       Date:  1999-01-15       Impact factor: 5.858

4.  Characterization of the pharmacokinetic and pharmacodynamic interaction between gamma-hydroxybutyrate and ethanol in the rat.

Authors:  Diederik K Van Sassenbroeck; Peter De Paepe; Frans M Belpaire; Walter A Buylaert
Journal:  Toxicol Sci       Date:  2003-04-15       Impact factor: 4.849

5.  Role of alcohol dehydrogenase in rat ethanol elimination kinetics.

Authors:  H Matsumoto; T Fujimiya; Y Fukui
Journal:  Alcohol Alcohol Suppl       Date:  1994

6.  Ethanol pharmacokinetics in white women: nonlinear model fitting versus zero-order elimination analyses.

Authors:  M S Mumenthaler; J L Taylor; J A Yesavage
Journal:  Alcohol Clin Exp Res       Date:  2000-09       Impact factor: 3.455

7.  Use of GHB compounds among college students.

Authors:  Alvaro Camacho; Scott C Matthews; Brian Murray; Joel E Dimsdale
Journal:  Am J Drug Alcohol Abuse       Date:  2005       Impact factor: 3.829

8.  Characterization of the pharmacokinetic interaction between nifedipine and ethanol in the rat.

Authors:  K M Boje; H L Fung
Journal:  J Pharmacol Exp Ther       Date:  1989-05       Impact factor: 4.030

9.  Liquid chromatographic-mass spectrometric determination of endogenous gamma-hydroxybutyrate concentrations in rat brain regions and plasma.

Authors:  Ho-Leung Fung; Eric Haas; Joseph Raybon; Jian Xu; Sun-Mi Fung
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2004-08-05       Impact factor: 3.205

10.  Effects of alcohol-metabolizing enzyme inhibitors and beta-lactam antibiotics on ethanol elimination in rats.

Authors:  J Shimada; T Miyahara; S Otsubo; N Yoshimatsu; T Oguma; T Matsubara
Journal:  Jpn J Pharmacol       Date:  1987-12
View more
  8 in total

1.  Development of a new pre- and post-processing tool (SADAPT-TRAN) for nonlinear mixed-effects modeling in S-ADAPT.

Authors:  Jurgen Bernd Bulitta; Ayhan Bingölbali; Beom Soo Shin; Cornelia Barbara Landersdorfer
Journal:  AAPS J       Date:  2011-03-03       Impact factor: 4.009

2.  Performance and robustness of the Monte Carlo importance sampling algorithm using parallelized S-ADAPT for basic and complex mechanistic models.

Authors:  Jurgen B Bulitta; Cornelia B Landersdorfer
Journal:  AAPS J       Date:  2011-03-04       Impact factor: 4.009

3.  Inhibition of 1,4-butanediol metabolism in human liver in vitro.

Authors:  Daniel Lenz; Martin Jübner; Katja Bender; Annette Wintermeyer; Justus Beike; Markus A Rothschild; Herbert Käferstein
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2011-05-02       Impact factor: 3.000

4.  Mechanistic toxicokinetic model for gamma-hydroxybutyric acid: inhibition of active renal reabsorption as a potential therapeutic strategy.

Authors:  Melanie A Felmlee; Qi Wang; Dapeng Cui; Samuel A Roiko; Marilyn E Morris
Journal:  AAPS J       Date:  2010-05-12       Impact factor: 4.009

5.  Use of a local sensitivity analysis to inform study design based on a mechanistic toxicokinetic model for γ-hydroxybutyric acid.

Authors:  Melanie A Felmlee; Wojciech Krzyzanski; Bridget L Morse; Marilyn E Morris
Journal:  AAPS J       Date:  2011-03-09       Impact factor: 4.009

6.  Toxicokinetics/Toxicodynamics of γ-hydroxybutyrate-ethanol intoxication: evaluation of potential treatment strategies.

Authors:  Bridget L Morse; Marilyn E Morris
Journal:  J Pharmacol Exp Ther       Date:  2013-06-28       Impact factor: 4.030

7.  γ-Hydroxybutyrate (GHB)-induced respiratory depression: combined receptor-transporter inhibition therapy for treatment in GHB overdose.

Authors:  Bridget L Morse; Nisha Vijay; Marilyn E Morris
Journal:  Mol Pharmacol       Date:  2012-05-04       Impact factor: 4.436

Review 8.  γ-Hydroxybutyric Acid: Pharmacokinetics, Pharmacodynamics, and Toxicology.

Authors:  Melanie A Felmlee; Bridget L Morse; Marilyn E Morris
Journal:  AAPS J       Date:  2021-01-08       Impact factor: 4.009

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.